Post-results note
Validation trial progressing, but eyes on the cash runway
Niels Granholm-Leth
Jesper Ingildsen
Oliver Røst Benneballe
2026-11-19
14:01 CET
The Q3 numbers were slightly above our expectations, driven by non-core products. However, we expect rising R&D costs in 2027 and see a need for additional funding. We reiterate our fair value range of DKK0.5–3.0, including a WACC of 17.0%.
Q3 trading update. Q3 sales and EBITDA were slightly above our forecasts supported by non-core products. Cash burn was in line with our expectation (Q3 cash: DKK53.2m). We raise our 2026e but trim 2027e EBITDA due to higher R&D costs for the validation trial, partly offset by higher RSUO sales at attractive gross margins. As of Q3, 59 US hospitals contributed to NGAL RSUO sales, and we find BioPorto likely to exceed the target of 60 hospitals in 2026.
ProNephro US adult validation trial progressing as planned, but focus is on cash runway. Expansion of the ProNephro NGAL trial to 900 patients to meet FDA requirements comes at a cost. We now estimate 2027 R&D costs of DKK53m, implying a funding need of ~DKK20m. On our calculations, we would not rule out BioPorto seeking external funding, even when factoring in the USD1.5m earnout from the antibody divestment potentially received over the next three years.
FDA approval of ProNephro in adults could be transformative. ProNephro is already FDA-approved for paediatric use, but we believe the FDA label expansion to adults is the key value driver, potentially unlocking ~57% of BioPorto’s estimated USD3bn TAM. Under the partnerships with Roche and Beckman Coulter, we see scope for scaling sales at attractive margins. However, it will depend on: 1) KDIGO guideline inclusion; 2) label expansion to adults; and 3) the ability to bridge the patent expirations in Q3 2028. US adults account for ~71% of our NPV SOTP.
Fair value range of DKK0.5–3.0 per share reiterated, using a risk-adjusted SOTP NPV (17.0% WACC, 1.3x beta and 5% liquidity premium): the upper end reflects approval of ProNephro NGAL in the adult indication alongside 10% additional revenue growth and 1% additional annual EBITDA margin expansion in our 20-year forecast period; the lower end assumes no FDA approval of ProNephro for adults and negative brand perception spill-over to RSUO.